Study on the prognosis of cardiomyocyte fibrosis in patients with severe valve disease undergoing transcatheter valve surgery

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052552

Enrollment

Unknown

Registered

2021-10-31

Start date

2021-11-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart valve disease

Interventions

Operation group:accept TAVI treatment

Non-operation group:Ductal valve repair

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients with severe heart valve diseases (including severe aortic stenosis, mitral insufficiency, tricuspid insufficiency and other valve diseases) undergoing transcatheter valve repair or replacement.

Exclusion criteria

Exclusion criteria: 1. There are contraindications for CMR examination: including but not limited to patients who have installed cardiac pacemaker (non-magnetic), implanted metal heart valve, non-magnetic vascular metal clip in the body, and patients within three months of pregnancy; 2. There are contraindications that cannot tolerate transcatheter heart valve repair or replacement: including but not limited to left ventricular thrombosis, left ventricular outflow tract obstruction, myocardial infarction within 30 days, anatomical morphology of valve root is not suitable for transcatheter heart valve repair or replacement, and the life expectancy is less than 1 year after correcting valve stenosis (such as malignant tumor).

Design outcomes

Primary

Measure	Time frame
Myocardial fibrosis;	—

Countries

China

Contacts

Public ContactLiu Hanxiong

Chengdu Third People's Hospital

lhanx@126.com+86 13551044286

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026